Mayr Patrick, Aumann Georg, Schaller Tina, Schenkirsch Gerhard, Anthuber Matthias, Märkl Bruno
Institute of Pathology, Zentralklinikum Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany.
Department of Visceral and Transplantation Surgery, Klinikum Augsburg, Augsburg, Germany.
Langenbecks Arch Surg. 2016 Mar;401(2):181-8. doi: 10.1007/s00423-016-1377-4. Epub 2016 Feb 16.
Lymph node size as a prognostic parameter has not been investigated well in the past. Recent data, however, have indicated that this parameter could be even more important than the lymph node count.
Based on the results of earlier studies, we analyzed the lymph node size and number of node-negative colon cancer patients with regard to survival. Data from 115 node-negative cases of colon cancer were analyzed. Lymph nodes with diameters ≤5 mm were defined as small, and all other lymph nodes were classified as intermediate/large in size and labeled LN5. All of the cases were categorized according to the number of LN5s. The LN5 very low (LN5vl) group included cases with less than two LN5s. All of the other cases were assigned to the LN5 low/high (LN5l/h) group.
The overall survival analysis revealed significantly worse outcomes for the LN5vl group, with a mean survival of 34 months compared to the LN5l/h group, with a mean survival of 40 months (P = 0.022). After adjusting for the pT1/2 and pT3/4 stages, we still found a significant outcome difference (P = 0.012). Multivariate analysis identified LN5vl and T-stage as being independently correlated with the outcome. The vast majority of LN5vl cases (91 %) were located in the left colon. The location itself, however, was not prognostic (P = 0.478).
LN5 count, as a marker of immune response, could be shown as being prognostic in node-negative colon cancer. Patients with low LN5 counts showed poor outcomes. These patients could perhaps profit from adjuvant chemotherapy.
淋巴结大小作为一个预后参数,过去尚未得到充分研究。然而,最近的数据表明,该参数可能比淋巴结计数更为重要。
基于早期研究结果,我们分析了淋巴结阴性结肠癌患者的淋巴结大小和数量与生存情况的关系。对115例淋巴结阴性结肠癌病例的数据进行了分析。直径≤5mm的淋巴结被定义为小淋巴结,所有其他淋巴结被归类为中等/大淋巴结,并标记为LN5。所有病例根据LN5的数量进行分类。LN5极低(LN5vl)组包括LN5少于两个的病例。所有其他病例被分配到LN5低/高(LN5l/h)组。
总生存分析显示,LN5vl组的预后明显较差,平均生存期为34个月,而LN5l/h组的平均生存期为40个月(P = 0.022)。在对pT1/2和pT3/4分期进行调整后,我们仍然发现存在显著的预后差异(P = 0.012)。多变量分析确定LN5vl和T分期与预后独立相关。绝大多数LN5vl病例(91%)位于左半结肠。然而,位置本身并无预后意义(P = 0.478)。
LN5计数作为免疫反应标志物,在淋巴结阴性结肠癌中可能具有预后价值。LN5计数低的患者预后较差。这些患者可能从辅助化疗中获益。